帕金森病疼痛的药物治疗

doi:10.12114/j.issn.1007-9572.2019.00.241

摘要/Abstract

摘要： 疼痛是帕金森病患者常见的一种非运动症状，患病率从40％~85％不等，疼痛的患者更容易合并其他非运动症状，导致患者的生活质量下降。本文归纳总结了帕金森病疼痛患者药物治疗的临床报道和其可能的作用机制，旨在为临床医生治疗帕金森病疼痛患者提供具有指导价值的参考信息，同时为完善帕金森病疼痛诊疗规范提出新的目标。

关键词: 帕金森病, 疼痛, 药物治疗, 综述, 临床实践

Abstract: Pain is a common non-motor symptom of Parkinson's disease（PD），with its prevalence ranging from 40% to 85%.PD patients with pain are more likely to complicated with other non-motor symptoms，which cause decrease in patients' quality of life.This article summarized the clinical reports of drug therapy for patients with Parkinson's pain and its possible mechanism of action.The aim of this paper was to provide clinicians with reference information for the treatment of patients in pain with Parkinson's disease and put forward new goals to improve the treatment standard for the disease pain.

Key words: Parkinson's disease, Pain, Medication, Review, Clinical practice

申雅恋,承欧梅. 帕金森病疼痛的药物治疗[J]. 中国全科医学, 2019, 22(16): 2008-2014. DOI: 10.12114/j.issn.1007-9572.2019.00.241.
SHEN Yalian,CHENG Oumei. Medical Treatment for Pain in Parkinson's Disease　[J]. Chinese General Practice, 2019, 22(16): 2008-2014. DOI: 10.12114/j.issn.1007-9572.2019.00.241.

参考文献

［1］BROEN P G，BRAAKSMA M，PATIJN J，et al．Prevalence of pain in Parkinson's disease：a systematic review using the modified QUADAS tool［J］．Movement Disorders Official Journal of the Movement Disorder Society，2012，27（4）：480．DOI：10.1002/mds.24054.
［2］VALKOVIC P，MINAR M，SINGLIAROVA H，et al．Pain in Parkinson's disease：a cross-sectional study of its prevalence，types，and relationship to depression and quality of life［J］．PLoS One，2015，10（8）：e0136541．DOI：10.1371/journal.pone.0136541.
［3］NèGREPAGèS L，REGRAGUI W，BOUHASSIRA D，et al．Chronic pain in Parkinson's disease：the cross-sectional French DoPaMiP survey［J］．Movement Disorders，2008，23（10）：1361-1369．DOI：10.1002/mds.22142.
［4］THOMPSON T，GALLOP K，CORRELL C U，et al．Pain perception in Parkinson's disease：a systematic review and meta-analysis of experimental studies［J］．Ageing Research Reviews，2017，35：74-86．DOI：10.1016/j.arr.2017.01.005.
［5］CHUDLER E H，DONG W K.The role of the basal ganglia in nociception and pain［J］．Pain，1995，60（1）：3-38．DOI：10.1016/0304-3959（94）00172-B.
［6］BORSOOK D，UPADHYAY J，CHUDLER E H，et al．A key role of the basal ganglia in pain and analgesia-insights gained through human functional imaging［J］．Molecular Pain，2010，6（1）：27．DOI：10.1186/1744-8069-6-27.
［7］BEISKE A G，LOGE J H，R?NNINGEN A，et al．Pain in Parkinson's disease：prevalence and characteristics［J］．Pain，2009，141（1/2）：173-177.
［8］FORD B.Pain in Parkinson's disease［J］．Movement Disorders，2010，25（4）：507-508．DOI：10.1002/mds.22716.
［9］WASNER G，DEUSCHL G.Pains in Parkinson disease：many syndromes under one umbrella［J］．Nature Reviews Neurology，2012，8（5）：284-294．DOI：10.1038/nrneurol.2012.54.
［10］CHAUDHURI K R，SCHAPIRA A H.Non-motor symptoms of Parkinson's disease：dopaminergic pathophysiology and treatment［J］．Lancet Neurology，2009，8（5）：464-474．DOI：10.1016/S1474-4422（09）70068-7.
［11］NEBE A，EBERSBACH G.Pain intensity on and off levodopa in patients with Parkinson's disease［J］．Movement Disorders Official Journal of the Movement Disorder Society，2010，24（8）：1233-1237．DOI：10.1002/mds.22546.
［12］STACY M.The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease［J］．Journal of Neural Transmission，2010，117（7）：837．DOI：10.1007/s00702-010-0424-5.
［13］CURY R G，GALHARDONI R，FONOFF E T，et al．Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms［J］．European Journal of Pain，2016，20（2）：151．DOI：10.1002/ejp.745.
［14］GEROIN C，GANDOLFI M，BRUNO V，et al．Integrated approach for pain management in Parkinson disease［J］．Current Neurology & Neuroscience Reports，2016，16（4）：28．DOI：10.1007/s11910-016-0628-7.
［15］GERDELAT-MAS A，SIMONETTA-MOREAU M，THALAMAS C，et al．Levodopa raises objective pain threshold in Parkinson's disease：a RⅢ reflex study［J］．Journal of Neurology Neurosurgery & Psychiatry，2007，78（10）：1140-1142．DOI：10.1136/jnnp.2007.120212.
［16］QUINN N P，LANG A E，KOLLER W C，et al．Painful Parkinson's disease［J］．Lancet，1986，327（8494）：1366．DOI：10.1016/S0140-6736（86）91674-0.
［17］FORD B，LOUIS E D，GREENE P，et al．Oral and genital pain syndromes in Parkinson's disease［J］．Movement Disorders Official Journal of the Movement Disorder Society，1996，11（4）：421-426．DOI：10.1002/mds.870110411.
［18］COON E A，LAUGHLIN R S.Burning mouth syndrome in Parkinson's disease：dopamine as cure or cause?［J］．Journal of Headache & Pain，2012，13（8）：687．DOI：10.1007/s10194-012-0421-1.
［19］FABBRI M，COELHO M，GUEDES L C，et al．Response of non-motor symptoms to levodopa in late-stage Parkinson's disease：results of a levodopa challenge test［J］．Parkinsonism & Related Disorders，2017，39：37．DOI：10.1016/j.parkreldis.2017.02.007.
［20］KARLSBORG M，KORBO L，REGEUR L，et al．Duodopa pump treatment in patients with advanced Parkinson's disease［J］．Ugeskrift for Laeger，2010，172（23）：1745．
［21］HONIG H，ANTONINI A，MARTINEZ-MARTIN P，et al．
Intrajejunal levodopa infusion in Parkinson's disease：a pilot multicenter study of effects on nonmotor symptoms and quality of life［J］．Movement Disorders Official Journal of the Movement Disorder Society，2009，24（10）：1468．DOI：10.1002/mds.22596.
［22］WANG Y，SUN S G，ZHU S Q，et al．Analysis of pramipexole dose–response relationships in Parkinson's disease［J］．Drug Design Development & Therapy，2017，11：83-89．DOI：10.2147/DDDT.S112723.
［23］PANDEY S，JAIN S.Pramipexole-associated fixed limb dystonia in Parkinson's disease［J］．Parkinsonism & Related Disorders，2016，31：159-160．DOI：10.1016/j.parkreldis.2016.08.018.
［24］MIRANDA M，CHANá P.Severe off-period facial dystonia in Parkinson's disease［J］．Movement Disorders Official Journal of the Movement Disorder Society，2000，15（1）：163-164．
［25］FACTOR S A.Literature review：intermittent subcutaneous apomorphine therapy in Parkinson's disease［J］．Neurology，2004，62（4）：12-17．DOI：10.1212/WNL.62.6_suppl_4.S12.
［26］LETVINENKO I V，ODINAK M M，MOGIL N V.Pain and depression in Parkinson's disease：new therapeutic possibilities of pramipexole［J］．Zh Nevrol Psikhiatr Im S S Korsakova，2008，108（11）：36-38.
［27］STUGINSKI-BARBOSA J，RODRIGUES G G，BIGAL M E，et al．Burning mouth syndrome responsive to pramipexol［J］．Journal of Headache & Pain，2008，9（1）：43-45．DOI：10.1007/s10194-008-0003-4.
［28］BARONE P，POEWE W，ALBRECHT S，et al．Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease：a randomised，double-blind，placebo-controlled trial［J］．Lancet Neurology，2010，9（6）：556-567．DOI：10.1016/S1474-4422（10）70106-X.
［29］TRENKWALDER C，KIES B，RUDZINSKA M，et al．Rotigotine effects on early morning motor function and sleep in Parkinson's disease：a double-blind，randomized，placebo-controlled study（RECOVER）［J］．Movement Disorders Official Journal of the Movement Disorder Society，2011，26（1）：90-99．DOI：10.1002/mds.23441.
［30］VALLDERIOLA F，COMPTA Y，APARICIO J，et al．Effects of night-time use of rotigotine on nocturnal symptoms in Parkinson's disease［J］．Parkinson's Disease，2015，21（8）：1-6．DOI：10.1155/ 2015/475630.
［31］WOITALLA D，KASSUBEK J，TIMMERMANN L，et al．Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch：a non-interventional prospective multicenter trial［J］．Parkinsonism Relat Disord，2015，21（3）：199-204．DOI：10.1016/j.parkreldis.2014.11.024.
［32］ROMAIN L，LUCILE B，JACQUES S，et al．Acute genital pain during non-motor fluctuations improved by apomorphine［J］．Movement Disorders Official Journal of the Movement Disorder Society，2013，28（5）：687-688．DOI：10.1002/mds.25379.
［33］RASCOL O，ZESIEWICZ T，CHAUDHURI K R，et al．A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease–associated chronic pain［J］．Journal of Clinical Pharmacology，2016，56（7）：852．DOI：10.1002/jcph.678.
［34］PARK D.Pramipexole-induced limb dystonia and its associated complex regional pain syndrome in idiopathic Parkinson's disease：a case report［J］．Medicine，2017，96（28）：e7530．DOI：10.1097/MD.0000000000007530.
［35］BUNTEN S，HAPPE S.Rotigotine transdermal system：a short review［J］．Neuropsychiatr Dis Treat，2006，2（4）：421-426．DOI：10.2147/nedt.2006.2.4.421.
［36］SCHELLER D，ULLMER C，BERKELS R，et al．The in vitro receptor profile of rotigotine：a new agent for the treatment of Parkinson's disease［J］．Naunyn Schmiedebergs Arch Pharmacol，2009，379（1）：73-86．DOI：10.1007/s00210-008-0341-4.
［37］KASSUBEK J，CHAUDHURI K R，ZESIEWICZ T，et al．Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease：a post hoc analysis of the RECOVER study［J］．BMC Neurology，2014，14（1）：42．DOI：10.1186/1471-2377-14-42.
［38］GIANLUIGIGESSA G.Apomorphine and other dopaminomimetics［M］．New York：Raven Press，1981.
［39］CATTANEO C，BARONE P，BONIZZONI E，et al．Effects of safinamide on pain in fluctuating Parkinson's disease patients：a post-hoc analysis［J］．Journal of Parkinsons Disease，2017，7（1）：95．DOI：10.3233/JPD-160911.
［40］TANEJA A，PASQUA O D，DANHOF M.Challenges in translational drug research in neuropathic and inflammatory pain：the prerequisites for a new paradigm［J］．European Journal of Clinical Pharmacology，2017，73（10）：1219-1236．DOI：10.1007/s00228-017-2301-8.
［41］DELLAPINA E.Emerging analgesic drugs for Parkinson's disease［J］．Expert Opin Emerg Drugs，2012，17（2）：157-171.
［42］TAKAHASHI T，TAMURA M，OSABE K，et al．A rare case of Parkinson's disease with severe neck pain owing to crowned dens syndrome［J］．Case Reports in Neurology，2014，6（2）：149-155．DOI：10.1159/000362514.
［43］TOMAZONI S S，FRIGO L，FERREIRA T C，et al．Effects of photobiomodulation therapy and topical non-steroidal anti-inflammatory drug on skeletal muscle injury induced by contusion in rats—part 1：morphological and functional aspects［J］．Lasers in Medical Science，2017，32（8）：1-10．DOI：10.1007/s10103-017-2346-z.
［44］BUHMANN C，WROBEL N，GRASHORN W，et al．Pain in Parkinson disease：a cross-sectional survey of its prevalence，specifics，and therapy［J］．Journal of Neurology，2017，264（4）：758-769．DOI：10.1007/s00415-017-8426-y.
［45］YUST K S，HERSHKOVITZ R，GUREVICH T，et al．Pain in extrapyramidal neurodegenerative diseases［J］．Clinical Journal of Pain，2016，33（7）：635．DOI：10.1097 /AJP.0000000000000437.
［46］ROGAWSKI M A，L?SCHER W.The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions［J］．Nature Medicine，2004，6：685-692．DOI：10.1038/nrn1430.
［47］IWASAKI Y，IKEDA K，SHIOJIMA T，et al．Increased plasma concentrations of aspartate，glutamate and glycine in Parkinson's disease［J］．Neuroscience Letters，1992，145（2）：175-177．DOI：10.1016/0304-3940（92）90015-Y.
［48］LEE H H，DEEB T Z，WALKER J A，et al．NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor mediated currents［J］．Channels，2011，14（6）：736-743．DOI：10.4161/chan.5.6.17952.
［49］SIDHU H S，SADHOTRA A.Current status of the new antiepileptic drugs in chronic pain［J］．Frontiers in Pharmacology，2016，7（45）：276．DOI：10.3389/fphar.2016.00276.
［50］SAVAGE N W.Burning mouth syndrome：patient management［J］．Australian Dental Journal，1996，41（6）：363-366.
［51］MO X，ZHANG J，FAN Y，et al．Thermal and mechanical quantitative sensory testing in Chinese patients with burning mouth syndrome：a probable neuropathic pain condition?［J］．Journal of Headache & Pain，2015，16（1）：84．DOI：10.1186/s10194-015-0565-x.
［52］HAGELBERG N，FORSSELL H，AALTO S，et al．Altered dopamine D2 receptor binding in atypical facial pain［J］．Pain，2003，106（1）：43-48．DOI：10.1016/s0304-3959（03）00275-6.
［53］LóPEZ-D'ALESSANDRO E，ESCOVICH L.Combination of alpha lipoic acid and gabapentin，its efficacy in the treatment of burning mouth syndrome：a randomized，double-blind，placebo controlled trial［J］．Medicina Oral Patología Oral Y Cirugía Bucaledinglesa，2011，16（5）：e635-640．DOI：10.4317/medoral.16942.
［54］WHITE T L，KENT P F，KURTZ D B，et al．Effectiveness of gabapentin for treatment of burning mouth syndrome［J］．Archives of Otolaryngology-Head and Neck Surgery，2004，130（6）：786-788．DOI：10.1001/archotol.130.6.786.
［55］HECKMANN S M，HECKMANN J G，UNGETHüM A，et al．Gabapentin has little or no effect in the treatment of burning mouth syndrome-results of an open-label pilot study［J］．European Journal of Neurology，2006，13（7）：e6-7．DOI：10.1111/j.1468-1331.2006.01294.x.
［56］UKAI K，FUJISHIRO H，OZAKI N.Effectiveness of low-dose pregabalin in three patients with Lewy body disease and central neuropathic pain［J］．Psychogeriatrics，2016，17（2）：115．DOI：10.1111/psyg.12192.
［57］ABE K，CHIBA Y，KATSUSE O，et al．A case of Parkinson disease with both visual hallucination and pain improved by gabapentin［J］．Clinical Neuropharmacology，2016，39（1）：55-56．DOI：10.1097/wnf.0000000000000122.
［58］LI C，SUGAM J A，LOWERYGIONTA E G，et al．Mu opioid receptor modulation of dopamine neurons in the periaqueductal gray/dorsal raphe：a role in regulation of pain［J］．Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology，2016，41（8）：2122．DOI：10.1038 /npp.2016.12.
［59］TOBALDINI G，REIS R A，SARDI N F，et al．Dopaminergic mechanisms in periaqueductal gray-mediated antinociception［J］．Behavioural Pharmacology，2018，29（1）：225-233．DOI：10.1097/FBP.0000000000000346.
［60］MARTíNRUIZ R，UGEDO L，HONRUBIA M A，et al．Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus［J］．Journal of Neurochemistry，2001，77（3）：762-775．DOI：10.1046/j.1471-4159.2001.00275.x.
［61］MADEO G，SCHIRINZI T，NATOLI S，et al．Efficacy and safety profile of prolonged release oxycodone in combination with naloxone（OXN PR）in Parkinson's disease patients with chronic pain［J］．Journal of Neurology，2015，262（9）：2164-2170．DOI：10.1007/s00415-015-7823-3.
［62］POELAERT J，KOOPMANSKLEIN G，DIOH A，et al．Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation［J］．Clinical Therapeutics，2015，37（4）：784-792．DOI：10.1016/j.clinthera.2015.02.010.
［63］TRENKWALDER C，CHAUDHURI K R，MARTINEZ-MARTIN P，et al．Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease（PANDA）：a double-blind，randomised，placebo-controlled trial［J］．Lancet Neurology，2015，14（12）：1161．DOI：10.1016/S1474-4422（15）00243-4.
［64］CIRCUITRY I.Central nervous system mechanisms of pain modulation［J］．Txetbook of Pain，2006，2（6）：44-46．DOI：10.1016/B0-443-07287-6/50012-6.
［65］WANG C T，MAO C J，ZHANG X Q，et al．Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease［J］．Molecular Pain，2017，13：1744806917691525．DOI：10.1177/1744806917691525.
［66］CAO L F，PENG X Y，HUANG Y，et al．Restoring spinal noradrenergic inhibitory tone attenuates pain hypersensitivity in a rat model of Parkinson's disease［J］．Neural Plasticity，2016，2016：6383240．DOI：10.1155/2016/6383240.
［67］TONG Q，LI Z，YUAN Y S，et al．Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms［J］．Parkinsonism & Related Disorders，2015，21（8）：882-887．DOI：10.1016/j.parkreldis.2015.05.016.
［68］DJALDETTI R，YUSTKATZ S，KOLIANOV V，et al．The effect of duloxetine on primary pain symptoms in Parkinson disease［J］．Clinical Neuropharmacology，2007，30（4）：201．DOI：10.1097/wnf.0b013e3180340319.
［69］BELLINGHAM G A，PENG P W.Duloxetine：a review of its pharmacology and use in chronic pain management［J］．Regional Anesthesia & Pain Medicine，2010，35（3）：294-303．DOI：10.1097/AAP.0b013e3181df2645.
［70］SANDYK R.Anticholinergic-induced analgesia：possible role for the cholinergic system in abnormal sensory symptoms in Parkinson's disease［J］．Postgraduate Medical Journal，1986，62（730）：749．DOI：10.1136/pgmj.62.730.749.
［71］CARDOSO F.Botulinum toxin in Parkinsonism：the when，how，and which for botulinum toxin injections［J］．Toxicon，2017，147（6）：107-110．DOI：10.1016/j.toxicon.2017.08.018.
［72］PACCHETTI C，ALBANI G，MARTIGNONI E，et al．Painful dystonia in Parkinson's disease treated with botulinum toxin［J］．Movement Disorders Official Journal of the Movement Disorder Society，1995，10（3）：333．DOI：10.1002/mds.870100317.
［73］TASSORELLI C，DE ICCO R，ALFONSI E，et al．Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of pisa syndrome in Parkinson disease：a placebo controlled study［J］．Parkinsonism & Related Disorders，2014，20（11）：1140-1144．DOI：10.1016/j.parkreldis.2014.07.015.
［74］CORDIVARI C，MISRA V P，CATANIA S，et al．Treatment of dystonic clenched fist with botulinum toxin［J］．Movement Disorders Official Journal of the Movement Disorder Society，2001，16（5）：907-913．DOI：10.1002/mds.1186.
［75］GUPTA A D，VISVANATHAN R.Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation：a case series and a pilot study［J］．Journal of Rehabilitation Medicine，2016，48（6）：559-562．DOI：10.2340/16501977-2094.
［76］BRUNO V A，FOX S H，MANCINI D，et al．Botulinum toxin use in refractory pain and other symptoms in Parkinsonism［J］．Canadian Journal of Neurological Sciences Le Journal Canadien Des Sciences Neurologiques，2016，43（5）：697．DOI：10.1017/cjn.2016.279.

[1]	王旭, 魏戌, 朱立国, 冯天笑, 王志鹏, 师彬. 医工结合的中医手法治疗脊柱退行性疾病疗效机制研究：思路与前景[J]. 中国全科医学, 2023, 26(33): 4118-4124.
[2]	辛功恺, 丛欣, 袁磊, 程悦彤, 倪翠萍, 张巍巍, 張平平, 刘宇. 失智症老年人综合评估工具的研究进展[J]. 中国全科医学, 2023, 26(33): 4103-4109.
[3]	张思宇, 周郁秋, 杜晓慧, 王正君. 精神病未治期及其早期干预的研究进展[J]. 中国全科医学, 2023, 26(33): 4110-4117.
[4]	孟江涛, 杨思宇, 孙蕾, 雷瑞宁, 赵晓霞. 弥散张量成像联合运动诱发电位评估脑梗死偏瘫患者运动功能预后价值的研究进展[J]. 中国全科医学, 2023, 26(32): 4098-4102.
[5]	路广琦, 庄明辉, 朱立国, 高景华, 魏戌, 李路广, 于杰. 腰椎管狭窄症的微创治疗实践指南：2022年美国疼痛与神经科学学会指南解读[J]. 中国全科医学, 2023, 26(32): 3995-4000.
[6]	王佳欣, 赵亚利. 国内外医疗团队合作评估工具系统综述[J]. 中国全科医学, 2023, 26(31): 3951-3962.
[7]	卫梦雨, 王佳佳, 张莹莹, 李春阳, 李建生. 阻塞性睡眠呼吸暂停患者报告结局测评工具研究现状分析[J]. 中国全科医学, 2023, 26(30): 3725-3733.
[8]	苑喜微, 南月敏. 线粒体融合蛋白2的结构和功能及其在肝脏疾病中作用机制的研究进展[J]. 中国全科医学, 2023, 26(30): 3841-3846.
[9]	肖雨倩, 白艳杰, 王岩, 陈淑颖, 陈丽敏, 孙可心, 万俊. 线粒体转移在脑卒中后认知障碍中的研究进展[J]. 中国全科医学, 2023, 26(30): 3833-3840.
[10]	刘煜, 岳婷, 杨东宇, 赵中亭, 杨吉勃, 朱田田. 自噬在类风湿关节炎发病机制中的研究进展[J]. 中国全科医学, 2023, 26(29): 3710-3714.
[11]	蒲瑜, 张吉翔, 董卫国. 铁死亡与炎症性肠病的研究进展[J]. 中国全科医学, 2023, 26(29): 3698-3703.
[12]	任延峰, 刘世蒙, 陶颖, 陈英耀. 抑郁症患者药物治疗偏好的系统综述：基于离散选择实验和优劣尺度法[J]. 中国全科医学, 2023, 26(28): 3559-3564.
[13]	梁雪梅, 王睿, 赵玉环, 徐天娇, 王伟, 孙伟东. 经颅低水平激光：一种治疗抑郁症的新方法[J]. 中国全科医学, 2023, 26(27): 3335-3341.
[14]	陈晓芬, 陈钰涵, 马娟. 炎症性肠病新型治疗方法的研究进展[J]. 中国全科医学, 2023, 26(27): 3349-3354.
[15]	汤时蓝, 谢可欣, 刘玲谕, 齐甜甜, 杨燕绥. 慢性意识障碍患者康复预后及照护研究进展[J]. 中国全科医学, 2023, 26(27): 3342-3348.